BACKGROUND: The aim of this study was better characterize the staining patterns of inverted papilloma (IP) with and without carcinoma by performing immunohistochemistry for p16, epidermal growth factor receptor (EGFR), p53, and cyclin D1 antibodies in a large patient cohort. METHODS: A total of 162 IP specimens were collected from 147 patients treated at the University of Michigan between 1996 and 2011. Twenty-two specimens contained carcinoma. Tumor was extracted for construction of 2 tissue microarrays and stained for p16, EGFR, p53, and cyclin D1. Tumor staining intensity and percentage staining were scored. RESULTS: Benign disease was positive for p16 in 64%, EGFR in 50%, p53 in 30%, and cyclin D1 in 76%. IP with carcinomatous degeneration was positive for p16 in 14%, EGFR in 71%, p53 in 62%, and cyclin D1 in 76%. The differences in staining positivity between benign and malignant disease reached significance for p16 and p53 only. Mean percentage staining by tumor surface area for IP and IP with carcinoma was 12% vs 7% for p16 (no statistical significance [NS]), 20% vs 34% for EGFR (NS), 4% vs 24% for p53 (p < 0.001), and 17% vs 21% for cyclin D1 (NS). CONCLUSION: Important characteristic staining pattern for IP with and without carcinoma are highlighted in this study. Unlike recent trends in human papilloma virus (HPV)-related head and neck malignancies, low expression of p16 is a marker for malignancy in this series. Positive staining for p53 correlates with the development of carcinoma in IP.
BACKGROUND: The aim of this study was better characterize the staining patterns of inverted papilloma (IP) with and without carcinoma by performing immunohistochemistry for p16, epidermal growth factor receptor (EGFR), p53, and cyclin D1 antibodies in a large patient cohort. METHODS: A total of 162 IP specimens were collected from 147 patients treated at the University of Michigan between 1996 and 2011. Twenty-two specimens contained carcinoma. Tumor was extracted for construction of 2 tissue microarrays and stained for p16, EGFR, p53, and cyclin D1. Tumor staining intensity and percentage staining were scored. RESULTS:Benign disease was positive for p16 in 64%, EGFR in 50%, p53 in 30%, and cyclin D1 in 76%. IP with carcinomatous degeneration was positive for p16 in 14%, EGFR in 71%, p53 in 62%, and cyclin D1 in 76%. The differences in staining positivity between benign and malignant disease reached significance for p16 and p53 only. Mean percentage staining by tumor surface area for IP and IP with carcinoma was 12% vs 7% for p16 (no statistical significance [NS]), 20% vs 34% for EGFR (NS), 4% vs 24% for p53 (p < 0.001), and 17% vs 21% for cyclin D1 (NS). CONCLUSION: Important characteristic staining pattern for IP with and without carcinoma are highlighted in this study. Unlike recent trends in human papilloma virus (HPV)-related head and neck malignancies, low expression of p16 is a marker for malignancy in this series. Positive staining for p53 correlates with the development of carcinoma in IP.
Authors: James S Lewis; Rebecca D Chernock; Xiao-Jun Ma; John J Flanagan; Yuling Luo; Ge Gao; Xiaowei Wang; Samir K El-Mofty Journal: Mod Pathol Date: 2012-05-18 Impact factor: 7.842
Authors: Mark E Prince; Mathew L Ubell; Jason Castro; Haruko Ogawa; Tetsuya Ogawa; Ajita Narayan; Augusto Paulino; Andrew Cole; Gregory T Wolf; Mark A Rubin; Robert H Lyons; Carol R Bradford; Thomas E Carey Journal: Head Neck Date: 2007-05 Impact factor: 3.147
Authors: Jens P Klussmann; Elif Gültekin; Soenke J Weissenborn; Ulrike Wieland; Volker Dries; Hans P Dienes; Hans E Eckel; Herbert J Pfister; Pawel G Fuchs Journal: Am J Pathol Date: 2003-03 Impact factor: 4.307
Authors: Niklas Reimers; Hans U Kasper; Soenke J Weissenborn; Hartmut Stützer; Simon F Preuss; Thomas K Hoffmann; Ernst Jan M Speel; Hans P Dienes; Herbert J Pfister; Orlando Guntinas-Lichius; Jens P Klussmann Journal: Int J Cancer Date: 2007-04-15 Impact factor: 7.396
Authors: Francis P Worden; Bhavna Kumar; Julia S Lee; Gregory T Wolf; Kitrina G Cordell; Jeremy M G Taylor; Susan G Urba; Avraham Eisbruch; Theodoros N Teknos; Douglas B Chepeha; Mark E Prince; Christina I Tsien; Nisha J D'Silva; Kun Yang; David M Kurnit; Heidi L Mason; Tamara H Miller; Nancy E Wallace; Carol R Bradford; Thomas E Carey Journal: J Clin Oncol Date: 2008-05-12 Impact factor: 44.544
Authors: Adam Scheel; Giant C Lin; Jonathan B McHugh; Christine M Komarck; Heather M Walline; Mark E Prince; Mark A Zacharek; Thomas E Carey Journal: Int Forum Allergy Rhinol Date: 2015-06-16 Impact factor: 3.858
Authors: M Re; F M Gioacchini; A Bajraktari; M Tomasetti; S Kaleci; C Rubini; A Bertini; G Magliulo; E Pasquini Journal: Eur Arch Otorhinolaryngol Date: 2017-04-21 Impact factor: 2.503
Authors: Marta Gamrot-Wrzoł; Paweł Sowa; Grażyna Lisowska; Wojciech Ścierski; Maciej Misiołek Journal: Biomed Res Int Date: 2017-11-09 Impact factor: 3.411